September 10 , 2022
                                                                          1151 days 
                                      938
                                    
                                   
								   
                                
                                
                                    
	- Bharat Biotech has received emergency use authorization for India’s 1st needle-free intranasal COVID-19 vaccine.
 
	- It has been named ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine.
 
	- As of now, the Drug Controller General of India has approved the intranasal vaccine for restricted emergency use in those aged above 18 years.
 
	- The Serum Institute’s COVISHIELD and Bharat Biotech’s COVAXIN were intravenous in nature.
 

                                 
                            
                                
                                Post Views: 
                                938